Cure8

Why This Matters

People with Turner syndrome have higher rates of other autoimmune diseases; this case shows that celiac disease and ulcerative colitis can coexist and lead to growth and bone health problems.

Treatment choices may be limited by drug side effects, and biologic therapy can be effective when immunomodulators and 5-ASA are not tolerated.

Who Should Pay Attention

Pediatric patients with Turner syndrome and their parents/caregivers; pediatric IBD clinicians; endocrinologists monitoring growth and bone health; multidisciplinary care teams.

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

This article is a pediatric case report describing a girl with Turner syndrome who developed celiac disease in childhood and later extensive ulcerative colitis with low bone mineral density.

Initial therapies (azathioprine and 5-ASA) were complicated by pancreatitis and enzyme recurrence on re-challenge, leading to discontinuation; infliximab induction achieved sustained clinical and near-complete histologic remission.

The authors emphasize lifelong multidisciplinary surveillance for autoimmune conditions, growth, and bone health in Turner syndrome. The report is grounded in the article abstract and case details; it does not provide generalizable outcomes beyond this single patient.

Key clinical points: screening for additional autoimmune disease in Turner syndrome, monitoring growth and bone density, and a treatment course complicated by drug-induced pancreatitis requiring a biologic.

For patients and caregivers: this is a single-case illustration of complex overlapping conditions rather than evidence of typical disease course or treatment efficacy. Discuss individual risks and treatment options with your care team.

Keep In Mind

This is a single-case report (abstract-level summary). It illustrates possible complications and the need for coordinated care but cannot establish typical prevalence, comparative treatment effectiveness, or long-term outcomes. Specific management decisions should be based on individual clinical assessment and guidelines.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationReports
PublisherMDPI AG
AuthorsMaria Rogalidou, Konstantina Dimakou, Kalliopi Stefanaki +3 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedSep 23, 2026, 12:00 AM
Content availableJournal abstract

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →